Dentons has advised Sobera Capital on the acquisition of a portfolio of minority and majority shares in companies mainly in the life sciences sector from Innoveas International Ltd. The acquired portfolio includes, among others, interests in Presidio Pharmaceuticals, EffRx Pharmaceuticals, M.O.R.E. Medical Solutions, Axellis Ventures and MyoScience. The assets are mainly based in Europe and the US.

Sobera Capital offers liquidity and management solutions for private equity investors. Apart from focusing on Secondary Directs, Sobera Capital buys shares in private equity funds and manages fund companies.

Innoveas acts at the interface of science and product development, transferring scientific ideas into startups and products.

Dentons provided comprehensive legal advice to Sobera Capital on the deal, in particular in relation to drafting the purchase agreements and structuring the fund to be acquired.

Advisor Sobera Capital:

Dentons (Berlin): Andreas Ziegenhagen (Partner, lead), Dr. Detlef Spranger (Counsel, M&A/negotiation lead), Matthias Hause (Associate, M&A)

Dentons (Munich): Simon Vogel (Partner), Danny Major (Associate, both fund formation)